Accretion Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lx4apujhghjzmg9lgwrit68c.pdf

Key Takeaways


Growth Engine: Volume, Capacity & Order Book

Jeet: "We are expecting the same momentum. So, it may be those figures which we are asking, but we cannot aim as of now."

Margin Reset: The Cost of Scaling

Jeet: "Percentage we will maintain by the time, but as of now we are growing. As we are growing so we have to make many expenses as well for the old registrations and more and more products and more and more countries to cater."

Product Mix & Margin Mechanics

Harshad Rathod: "Margins are different according to the product mix. So, we are not that much clearly say the somehow product just like a tablet gives a more margin or liquid gives a little margin, less margin as compared to tablet or external preparation that ointment cream that give you the good margin."

Regulatory & Geographic Expansion


Balance Sheet & IPO Deployment

Harshad Rathod: "Going forward, our financial focus will remain on maintaining profitable growth, enhancing working capital efficiency, and ensuring consistent return ratio to prudent capital management."

Business Model & Client Profile


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth momentumExpects same momentum (130% YoY rate) to continueH2 FY26 and subsequent years
Malawi export contributioncGMP approval to contribute meaningfully to export revenuesNo specific timeline
Philippines & Ghana market entryPlant audits completed; registration process underway1-2 years for registration completion
EBITDA margin recoveryReturn to historical 20%-21% levelOnce business reaches maturity and registration expenses reduce; no date given
Branded sales expansionSell under own brand name for better marginsOnce Accretion name is established in markets through merchant exporters; no date given
Capacity expansion revenue40% capacity increase completedRevenue contribution depends on product mix; no quantification provided

Key Metrics

MetricH1 FY26
Revenue from operations (H1)₹43.74 cr, +135.59% YoY vs ₹18.56 cr in H1 FY25
Revenue from operations (FY25 full year)₹57.4 cr, ~70% YoY growth
EBITDA (excl other income, H1)₹7.07 cr, +63% YoY vs ₹4.34 cr in H1 FY25
EBITDA margin (H1)16.17%, down from ~23.5% previously; scaling expenses and product mix impact
EBITDA margin (FY25 full year)~21%
Profit after tax (H1)₹4.75 cr, +92.81% YoY vs ₹2.46 cr in H1 FY25
PAT margin (H1)10.87%
PAT margin (FY25 full year)~12%
Return on capital employed (FY25)38%
IPO proceeds raised₹29.75 cr, deployed for capacity expansion, debt repayment, and working capital
Production capacity increase post-IPO40%
Export revenue share~70% of business
Domestic revenue share~30% of business
Direct export share~10% of total revenue
Working capital days (average)180–190 days
Working capital days (export)~185–190 days
Working capital days (domestic)~140–150 days
Products under registrationMore than 100 across multiple countries
Plant registration cost per country$15,000–$20,000 approx
Product registration cost per country$2,000–$5,000 approx
Balance sheet size (FY24)~₹27 cr
Balance sheet size (current)~₹60 cr
Inventory₹20 cr
Revenue momentum expectationSame growth momentum as H1 expected for upcoming periods; full-year revenue of ₹120–130 cr implied (per an analyst's math)